Connecting clinical care, data and research
PartnershipsContact
← Back to publications

RESEARCH PUBLICATION / 2026

Original Article

SGLT2 inhibitors and risk of new-onset rheumatoid arthritis in patients with type 2 diabetes

The association between SGLT2 inhibitors and rheumatoid arthritis risk in type 2 diabetes: findings from large-scale emulated target trials.

Frontiers in immunology

Citation & Authors

Front Immunol. 2026;17:1867117.

Fu-Shun Yen; Shiow-Ing Wang; Chih-Cheng Hsu; Sung Huang Laurent Tsai; Chii-Min Hwu; James Cheng-Chung Wei

ABSTRACT · CHINESE TRANSLATION

Translated abstract

Translated from the licensed abstract via the Chinese version. This is not an official journal translation.

Preface

The global prevalence of rheumatoid arthritis (RA) is increasing, and some glucose-lowering drugs have been reported to reduce its risk. This multicenter target trial emulation compared incident RA risk in patients with type 2 diabetes receiving SGLT2 inhibitors or other treatments.

method

TriNetX identified 4,991,988 patients with type 2 diabetes between January 1, 2016, and June 30, 2023. Separate propensity score-matched comparisons yielded 310,507 pairs for SGLT2 inhibitors versus sulfonylureas, 206,069 pairs versus DPP-4 inhibitors, and 80,846 pairs versus pioglitazone. Kaplan–Meier methods assessed the relative risk of RA across groups. Subgroup analyses considered sex, age, race, obesity, HbA1c, and eGFR, and an additional intention-to-treat sensitivity analysis was conducted.

result

Compared with sulfonylureas, SGLT2 inhibitors were significantly associated with a lower risk of incident RA (HR 0.899; 95% CI 0.835–0.968). Comparisons with DPP-4 inhibitors (0.914; 0.831–1.005) and pioglitazone (0.922; 0.796–1.068) were not significant. Kaplan–Meier curves also showed fewer RA events with SGLT2 inhibitors than with sulfonylureas (log-rank p=0.004). Results were consistent across analyzed subgroups, and sensitivity analyses supported the robustness of this comparison.

discuss

In patients with type 2 diabetes, SGLT2 inhibitors were associated with a lower risk of incident RA than sulfonylureas. Given the observational design, however, the findings should be interpreted as associations rather than causal evidence.

Original work: Author of the above paper. Source:Public Summary ↗. This translation is based on the Chinese rendering of the original English abstract.

Original work license:CC BY ↗;Translations are subject to the same licensing conditions.